333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985 by Van Herpen, C.M, Banerji, U, Mommers, E.C, Koper, N.P, Goedings, P, Lopez, J, Awada, A, Fiebrich, H.B, Aftimos, P.G

Get full text